Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
First Claim
1. A method for the systematic, multi-tiered treatment of coronary artery disease by delivey of a formulation comprising one or more therapeutic growth factor proteins, the method comprising the steps of:
- a.) selecting a patient displaying symptoms of acute coronary artery disease;
b.) administrating at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof by inhalation therapy;
c.) monitoring one or more clinical indicators of acute coronary artery disease;
d.) determining, based on monitoring the one or more clinical indicators of coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is neceasary;
e.) depending on the results of the step d.), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof; and
f.) repeating steps c.) through e.) until there is a clinical indication of amelioration of the symptoms of acute coronary artery disease in the patient, or until there is a contraindication to continued treatment.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.
-
Citations
24 Claims
-
1. A method for the systematic, multi-tiered treatment of coronary artery disease by delivey of a formulation comprising one or more therapeutic growth factor proteins, the method comprising the steps of:
-
a.) selecting a patient displaying symptoms of acute coronary artery disease;
b.) administrating at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof by inhalation therapy;
c.) monitoring one or more clinical indicators of acute coronary artery disease;
d.) determining, based on monitoring the one or more clinical indicators of coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is neceasary;
e.) depending on the results of the step d.), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof; and
f.) repeating steps c.) through e.) until there is a clinical indication of amelioration of the symptoms of acute coronary artery disease in the patient, or until there is a contraindication to continued treatment. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A method for the systematic, multi-tiered treatment of chronic coronary artery disease by delivery of a formulation comprising one or more therapeutic growth factor proteins, the method comprising the steps of:
-
a.) selecting a patient displaying symptoms of chronic coronary artery disease;
b.) administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof, by inhalation therapy;
c.) monitoring one or more clinical indicators of chronic coronary artery disease;
d.) determining, based on monitoring the one or more clinical indicators of chronic coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is necessary;
e.) depending on the results of step d.), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof; and
f.) repeating steps c.) through e.) until there is a clinical indication of amelioration of the symptoms of chronic artery disease in the patient, or until there is a contraindication to continued treatment. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24)
-
Specification